Introduction
============

Palmar and foot hyperhidrosis is a common disease caused by excessive activation of the sympathetic nervous system leading to autonomic excessive secretion of head and facial sweat glands thus resulting in the increased sweating ([@b1-etm-0-0-5873]). The incidence rate of palmar and foot hyperhidrosis is approximately 1.0% in the Western countries. The epidemiological investigation in China displays that the incidence rate is approximately 4.6% in college and secondary school students in Fuzhou.

The corresponding symptoms generally can be found during the elementary school period among patients with palmar and foot hyperhidrosis. Although the disease cannot affect the health and longevity of patients, it causes inconvenience to their work, study and social life, and have a greater impact on their quality of life ([@b2-etm-0-0-5873],[@b3-etm-0-0-5873]). The therapies of palmar and foot hyperhidrosis include internal medicine and surgery. The effect of drug therapy is poor, with greater side effects, and the long-term use is easy to produce immune tolerance, and relapse easily occurs once the drug is discontinued ([@b4-etm-0-0-5873]). In the 1980s, the clinical application of thoracoscope contributed to the rapid development of the minimally invasive surgery of palmar and foot hyperhidrosis. It has the advantages of small trauma, quick recovery and remarkable curative effect ([@b5-etm-0-0-5873]).

Minimally invasive surgery was conducted in patients with palmar and foot hyperhidrosis in this study and obtained satisfactory curative effect.

Materials and methods
=====================

### General information

Seventy-six patients with palmar and foot hyperhidrosis admitted to Yunnan University Hospital from August 2014 to July 2016 were selected and randomly divided into control group (n=38) and observation group (n=38) using the random number table. Inclusion criteria: i) Patients met the diagnostic criteria of primary hyperhidrosis; ii) patients with main clinical symptoms of much palmar and foot sweating, lasting more than six months, over more than once every week; iii) patients with hyperhidrosis affecting daily activities; and iv) patients signed the inform consent. Exclusion criteria: i) Patients with severe heart, brain, liver or psychiatric disorders; and ii) patients with severe coagulation disorders and drug allergy to the drug. The differences in general data of patients in two groups were not statistically significant (P\>0.05) ([Table I](#tI-etm-0-0-5873){ref-type="table"}). The study was approved by the Ethics Committee of Sun Yat-Sen University (Guangdong, China).

### Drug therapy

Drug therapy was used in the control group. Before treatment, patients underwent a general physical examination. Patients with a history of drug allergy were excluded, and the range of sweating was measured by the iodine-starch test. Twenty injection sites were designed at each side of the hands and feet (1.0 cm apart). Botulinum toxin type A (100 units) was diluted using 3 ml sodium chloride solution, and subcutaneous injection was conducted according to the designed injection sites (the amount of injection at each injection site was approximately 2.5 units). Attention was paid that the needle was not too deep to prevent the weakening of muscle strength during injection. The condition of patients was closely observed for approximately 30 min after injection to prevent the occurrence of drug allergy.

### Surgical therapy

Patients in the observation group underwent laparoscopic thoracic-4 sympathetic chain combined with thoracic-3 branch amputation. Before operation, chest X-ray, electrocardiogram and blood test and urine routine examination were performed to confirm the indication of operation. General anesthesia was performed with intravenous compound single-lumen endotracheal intubation. The patient was in a semi-supine position, with the upper arms reaching approximately 90 degrees to fully expose the bilateral armpits. The sequence of operation was followed by first right and then left. The incision was performed through the third intercostal space (approximately 1 cm length of incision), followed by placement of needle sleeve (Trocar). By adopting single-hole double-channel video thoracoscope, electric coagulation hook was placed. Through the observation by thoracoscope, the location of R3 (the third rib surface sympathetic ganglia) and R4 (the fourth rib surfaces) were determined. An electric coagulation hook was used to cut off the R4 trunk and perform repeated cauterization to ensure complete separation of the nerve stoma; subsequently, approximately 2 cm length was cut along the rib surface to the outside, so as to observe the existence of collateral fibers, and to ensure the amputation. R3 trunk outside was observed for any collateral fibers. If existing, the electric coagulation would break it, and the incision approximately 1.5 cm in length was foreseeingly made to outside, and if it was completely burned was observed, avoiding the damage to the trunk of R3. At the end of the operation, whether active bleeding was observed, and whether the bilateral hands were dry and warm was determined. After the observation by thoracoscope displayed the swell of lungs, endoscope was withdrawn, annular tubes were extracted and the incision was sutured. If the hands and feet were still cold and damp, the complete disconnection of broken ends and collateral branches of sympathetic nerve should be examined again before the withdrawal of the endoscope.

### Index detection

Fasting venous blood (3--5 ml) was collected from patients in the two groups before and at one week after treatment, followed by separation and extraction of serum. The levels of serum C-reactive protein (CRP), interleukin-6 (IL-6), IL-10 and tumor necrosis factor-α (TNF-α) in patients were measured by enzyme-linked immunosorbent assay (ELISA), and related kits were provided by Zhejiang Ikon Co., Ltd., Zhejiang, China. The operations were performed strictly according to the instructions. The optical density (OD) value was read at 450 nm of wavelength by a microplate reader (Jiangsu Potebio Co., Ltd., Jiangsu, China), followed by calculation of levels of CRP, IL-6, IL-10 and TNF-α. The levels of immunoglobulin G (IgG), IgA and IgM in patients were detected by immunoturbidimetry, and related kits were provided by Shanghai Yanjin Biotechnology Co., Ltd., Shanghai, China. The operations were strictly performed according to the instructions. The contents of IgG, IgA and IgM in the sample were calculated by measuring turbidity of reaction liquid and comparing with standard samples.

### Follow-up

After treatment, follow-up was conducted by outpatient, telephone, network and other methods for 6 months, so as to understand the improvement and recurrence of the primary sweating site and assess the quality of life.

### Evaluation criteria

Criteria for judging the severity of palmar and foot hyperhidrosis: a) mild, it was moist when sweating; b) moderate, sweating soaked a handkerchief; c) severe, sweat dropped as beads of sweat.

The curative effect was evaluated, and the criteria were as follows: a) cured, after 3 months of treatment, hands and feet were warm and dry, with no moisture and sweat in the quiet state and suitable room temperature; b) effective, after treatment, the wet and sweating conditions of hand and foot were improved significantly, with slight sweating under normal conditions; c) ineffective, after 3 months of treatment, severe sweating occurred in patients or sweating did not improve significantly compared with that before treatment. Therapeutic total effective rate = cure rate + effective rate.

Fasting venous blood (5 ml) was collected from patients in the morning before and at one week after treatment, followed by separation and extraction of serum and stored at −20°C. The levels of serum CRP, IL-6, IL-10 and TNF-α in patients were measured by ELISA before treatment and at one week after treatment. The levels of immunoglobulin IgG, IgA and IgM were detected by immunoturbidimetry.

The quality-of-life index (iQOL) was used to assess the quality of life in patients before and after treatment ([@b6-etm-0-0-5873]). According to the impact of disease on the quality of life in patients, the severity was divided into 0--3 points (0 point indicates no impact on quality of life; 3 points indicate a serious impact on quality of life), and the score was negatively related to the quality of life of patients.

### Statistical analysis

Data were processed by SPSS 19.0 (SPSS Inc., Chicago, IL, USA) software. Measurement data were expressed by mean ± standard deviation, and t-test was adopted. Count data were expressed by percentage, and Chi-square test was utilized. The rank sum test was used for curative effect. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Three months later, the therapeutic effective rate in the observation group was 94.74%, which was significantly higher than 73.23% in the control group, and the difference was statistically significant (P\<0.05) ([Table II](#tII-etm-0-0-5873){ref-type="table"}).

### Comparisons of levels of CRP, IL-6, IL-10 and TNF-α in the patients of the two groups

Before treatment and at one week after treatment, CRP levels in observation group were 2.57±0.24, 10.37±1.23 mg/l; IL-6 levels were 6.43±4.24, 31.67±3.23 pg/ml; IL-10 levels were 8.43±2.24, 15.37±3.23 pg/ml; and TNF-α levels were 9.43±5.24, 27.67±3.23 pg/ml. Before treatment and at one week after treatment, CRP levels in observation group were 2.65±0.35, 9.63±2.15 mg/l; IL-6 levels were 17.24±4.36, 29.58±3.74 pg/ml; IL-10 levels were 8.68±2.58, 13.67±3.23 pg/ml; TNF-α levels were 9.36±5.17, 25.85±4.43 pg/ml. The serum levels of CRP, IL-6, IL-10 and TNF-α in the patients of the two groups after treatment were increased compared with those before treatment (P\<0.05). There were no statistically significant differences in patients between two groups (P\>0.05) ([Figs. 1](#f1-etm-0-0-5873){ref-type="fig"}--[4](#f4-etm-0-0-5873){ref-type="fig"}).

### Comparisons of immunological indexes in patients of the two groups

After treatment for one week, IgG, IgM and IgA in patients of the two groups were obviously increased (P\<0.05). The differences were not statistically significant in patients between two groups (P\>0.05) ([Table III](#tIII-etm-0-0-5873){ref-type="table"}).

### Comparisons of quality of life in patients of the two groups

Through the follow-up for six months, it could be seen that iQOL scores in patients of the two groups were remarkably decreased, which was more significant in observation group (P\<0.05) ([Table IV](#tIV-etm-0-0-5873){ref-type="table"}).

Discussion
==========

The pathogenesis of palmar and foot hyperhidrosis is not yet entirely clear, and anxiety, stress and hot weather all contribute to this disease. Most studies suggest that it is closely related to the overactivity of sympathetic nerve ([@b7-etm-0-0-5873]). The secretion of sweat glands in the human body is governed by sympathetic nerves, and the sympathetic nerve chain belongs to the autonomic nervous system, which consists of sympathetic ganglia and intersegmental branches, and is symmetrically distributed on both sides of the human spine ([@b8-etm-0-0-5873]). The sympathetic nerve, which usually controls the sweat glands of hands and feet, is located at the levels of thoracic-2 to the thoracic-6 spinal segments and controls the sweat glands by releasing acetylcholine ([@b9-etm-0-0-5873]). Studies have revealed that sympathetic nerve fiber myelin sheath is thickened in patients with palmar and foot hyperhidrosis than that in normal people, thus accelerating the speed of sympathetic nerve conduction, so the excitability in patients stimulated by nervousness, excitement, stress and fever in the waking state will be enlarged, thereby increasing the sweat secreted by sweat glands; palmar and foot hyperhidrosis usually occurs during the young period or adolescence, which will continue to exist for life; it has a strong heredity with genetic probability in 30--40% ([@b10-etm-0-0-5873],[@b11-etm-0-0-5873]).

Palmar and foot hyperhidrosis can be treated by medication and surgery; therein, medication includes topical medication, oral medication, direct current, iontophoresis and botulinum toxin injection ([@b12-etm-0-0-5873]). Commonly used drugs are anticholinergic agents that inhibit the action of sweat glands by competing against acetylcholine muscarinic receptors, reducing the amount of perspiration thus treating them. However, it has many side effects such as intestinal reaction, elevated intraocular pressure, dry mouth, blood pressure drop and tachycardia. Surgical treatment is usually performed by sympathectomy currently, thus inhibiting the excessive secretion of sweat glands ([@b13-etm-0-0-5873]). The results of this study displayed that the therapeutic effective rate in the observation group was 94.74%, which was significantly higher than 73.23% in the control group, and the difference was statistically significant (P\<0.05). The reason is that botulinum toxin type A can inhibit acetylcholine releasing from presynaptic nerve terminals through acting on cholinergic nerve endings, thus inhibiting the secretion of sweat gland; however, long-term injection is prone to induce immune tolerance, pain of injection site and amyasthenia in patients; although they can be treated in the short-term, the disease easily relapses, which shows an uncertain long-term curative effect ([@b14-etm-0-0-5873]). The conduction of sympathetic nerve can be effectively blocked through burning corresponding sympathetic segment and extending to the outside, namely thoracoscopic thoracic-4 sympathetic nerve chain combined with thoracic-3 branch amputation, thus inhibiting sweat glands; once treated, it is difficult to relapse, and it has certain long-term curative effect, smaller incision of minimally invasive surgery, not obvious postoperative scar and higher satisfaction in patients ([@b15-etm-0-0-5873]).

Surgical trauma, combined with anesthesia and other stress reactions will inhibit the immune function and easily induces immune dysfunction, accompanied by inflammatory responses, thus leading to postoperative infection, which is not conducive to postoperative recovery of patients. CRP is an acute-phase reactive protein with high sensitivity. It can play a regulatory role by stimulating cell activation, which is commonly utilized as a marker of trauma and inflammation in the clinical practice. When the organism is damaged or has a bacterial infection, the concentration of CRP increases obviously ([@b16-etm-0-0-5873]--[@b18-etm-0-0-5873]). IL-6 is an important member of the interleukin family and plays a diverse role in the body\'s immune response and apoptosis ([@b19-etm-0-0-5873]). IL-10 can inhibit the secretion of a variety of proinflammatory cytokines, and the upregulation of its level can make the body into a highly reactive state of humoral immunity ([@b20-etm-0-0-5873]). As a polypeptide cytokine, TNF-α can synergistically interact with inflammatory mediators such as IL-6 and IL-10, which is an important cytokine mediating injury and infection; it is closely related to host defense function ([@b21-etm-0-0-5873]). The results of this study displayed that the serum levels of CRP, IL-6, IL-10 and TNF-α in patients of the two groups were higher at one week after treatment than those before treatment (P\<0.05), and there were no significant differences between the two groups (P\>0.05). The reason is that multi point injection therapy makes stronger sense of pain in patients, and the stress reaction can lead to abnormally increased secretion of serum cytokines; especially, the surgical treatment is more likely to cause inflammatory reaction after operation, so CRP, IL-6, IL-10 and TNF-α levels were increased compared with those before treatment. Minimally invasive surgery utilized in observation group can reduce the use of surgical instruments, plus the reduction of surgical incision length, so that the trauma is less. During the operation, the nerve was cut off by electric coagulation under direct vision using thoracoscope, and no drainage was performed after the operation, so as to reduce the stress reaction compared with routine surgery in patients and effectively decrease the occurrence of infection. Patients recovered usually at approximately one week after operation, fully demonstrating the concept of minimally invasive surgery.

After treatment for one week, IgG, IgM and IgA in patients of the two groups were obviously increased (P\<0.05), and the differences in patients between two groups were not statistically significant (P\>0.05). The reason is that humoral immunity in normal human will remain at a low level; the body affected by trauma will produce slight infection, while self-immune regulation occurs in the body, thus increasing the immunoglobulin IgG, IgM and IgA levels and enhancing the ability of resistance. Thoracoscopic sympathectomy has advantages of more accurate positioning, minimally invasive processing and safety, which causes less injury to normal immune function of the body, and it has little influence on the normal increase of postoperative immunoglobulin IgG, IgM and IgA levels in patients, which is conducive to the rapid recovery in patients after operation.

In summary, minimally invasive surgery adopted to treat palmar and foot hyperhidrosis has more significant effect compared with drug therapy. It causes slight postoperative inflammatory reaction and has less influence on the immune function of patients, and it can also improve the quality of life in patients. Thus, it is the ideal method for the treatment of palmar and foot hyperhidrosis, which is worthy of clinical application.
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###### 

General data of objects of study.

  Characteristics              Control group (n=38)   Observation group (n=38)   t/χ^2^ value   P-value
  ---------------------------- ---------------------- -------------------------- -------------- ---------
  Sex (male/female)            24/14                  26/12                      0.234          0.629
  Age (year old)               18--40                 18--45                                    
  Average age (year old)       25.36±5.63             25.85±5.73                 0.376          0.708
  Duration of illness (year)   11.62±2.46             11.25±2.37                 0.668          0.506
  BMI (kg/m^2^)                23.43±3.27             22.87±3.58                 0.712          0.479
  Severe degree (n, %)                                                                          
    Mild                         4 (10.52)            3 (7.89)                   0.001          0.999
    Moderate                   16 (42.11)             19 (50.00)                 0.211          0.645
    Severe                     18 (47.37)             16 (42.11)                 0.053          0.818

###### 

Comparison of curative effect in patients of the two groups (n, %).

  Group         N    Cured        Effective     Ineffective   Totally effective
  ------------- ---- ------------ ------------- ------------- -------------------
  Observation   38   27 (71.05)     9 (23.68)   2 (5.26)        6 (94.74)
  Control       38   12 (31.58)   16 (42.11)    10 (26.32)    18 (73.23)

The curative effect in two groups is processed by rank sum test, Z=3.590, P\<0.001.

###### 

Comparisons of immunological indexes in patients of the two groups (g/l).

                IgA                             IgG                               IgM                                               
  ------------- ----------- ----------- ------- --------- ----------- ----------- ------- --------- ----------- ----------- ------- ---------
  Observation   1.03±0.26   1.69±0.45   7.828   \<0.001   5.15±1.63   9.05±2.67   7.685   \<0.001   1.15±0.43   1.83±0.36   7.475   \<0.001
  Control       1.04±0.27   1.67±0.34   8.945   \<0.001   5.17±1.45   9.07±2.42   8.522   \<0.001   1.17±0.35   1.88±0.47   7.469   \<0.001
  t-value       0.164       0.219                         0.057       0.034                         0.222       0.521               
  P-value       0.870       0.827                         0.955       0.973                         0.825       0.604               

###### 

iQOL in patients of the two groups.

                     iQQL score                         
  ------------- ---- ------------ ----------- --------- ---------
  Observation   38   2.36±0.32    0.41±0.12   35.173    \<0.001
  Control       38   2.35±0.33    1.18±0.87     7.751   \<0.001
  t-value            0.134        5.405                 
  P-value            0.894        \<0.001               
